Skip to main content

Leukaemia: Drugs

Volume 463: debated on Tuesday 17 July 2007

To ask the Secretary of State for Health pursuant to the answer of 10 July 2007, Official Report, column 1450W, on leukaemia: drugs, what the reasons were for deciding not to refer dasatnib to the National Institute for Health and Clinical Excellence; and in what circumstances the drug would be considered for referral in the future. (149958)

The Department has not received a proposal from the National Institute for Health and Clinical Excellence (NICE) for an appraisal of dasatinib for chronic myeloid leukaemia. However, I understand that NICE is currently considering a proposal for an appraisal of this treatment against its published criteria for the selection of topics.